Zobrazeno 1 - 10
of 125
pro vyhledávání: '"David W. Goodrich"'
Autor:
Fabio Quaglia, Shiv Ram Krishn, Khalid Sossey-Alaoui, Priyanka Shailendra Rana, Elzbieta Pluskota, Pyung Hun Park, Christopher D. Shields, Stephen Lin, Peter McCue, Andrew V. Kossenkov, Yanqing Wang, David W. Goodrich, Sheng-Yu Ku, Himisha Beltran, William K. Kelly, Eva Corey, Maja Klose, Christine Bandtlow, Qin Liu, Dario C. Altieri, Edward F. Plow, Lucia R. Languino
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Androgen deprivation therapies aimed to target prostate cancer (PrCa) are only partially successful given the occurrence of neuroendocrine PrCa (NEPrCa), a highly aggressive and highly metastatic form of PrCa, for which there is no effective
Externí odkaz:
https://doaj.org/article/3eeb18d3b89f4f6090553922e8d4285e
Autor:
Rahul Kumar, Ajay K. Chaudhary, Jordan Woytash, Joseph R. Inigo, Abhiram A. Gokhale, Wiam Bshara, Kristopher Attwood, Jianmin Wang, Joseph A. Spernyak, Eva Rath, Neelu Yadav, Dirk Haller, David W. Goodrich, Dean G. Tang, Dhyan Chandra
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 13 (2022)
Mitochondrial proteostasis, regulated by the mitochondrial unfolded protein response (UPRmt), is crucial for maintenance of cellular functions and survival. Elevated oxidative and proteotoxic stress in mitochondria must be attenuated by the activatio
Externí odkaz:
https://doaj.org/article/3d0a007713ee43918ce086163783b2d9
Autor:
Meenalakshmi Chinnam, Chao Xu, Rati Lama, Xiaojing Zhang, Carlos D. Cedeno, Yanqing Wang, Aimee B. Stablewski, David W. Goodrich, Xinjiang Wang
Publikováno v:
PLoS Genetics, Vol 18, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/81e741ca35f94e0a98039457fdb07ecc
Autor:
Mauricio Flores, David W. Goodrich
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
The retinoblastoma susceptibility gene (RB1) is the first tumor suppressor gene discovered and a prototype for understanding regulatory networks that function in opposition to oncogenic stimuli. More than 3 decades of research has firmly established
Externí odkaz:
https://doaj.org/article/355a713c13a94562bd220fe43ab737fd
Autor:
Dongbo Xu, Li Wang, Kyle Wieczorek, Yali Zhang, Zinian Wang, Jianmin Wang, Bo Xu, Prashant K. Singh, Yanqing Wang, Xiaojing Zhang, Yue Wu, Gary J. Smith, Kristopher Attwood, Yuesheng Zhang, David W. Goodrich, Qiang Li
Publikováno v:
Cancers, Vol 14, Iss 10, p 2511 (2022)
Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Therefore, there is an urgent unmet need to develop clinically relevant preclinical models so that factors governing immunot
Externí odkaz:
https://doaj.org/article/55f5e29ecd1d41c9a28a5c3b4f903e46
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant activation of kinase signaling and occur in ∼15% of non-small cell lung cancers (NSCLC). Patients diagnosed with EGFR-mutant NSCLC have good initial clinical
Externí odkaz:
https://doaj.org/article/fd9bf04414b5437d8f22b9b1581aa1bc
Autor:
Sandeep Kumar, Ajay K. Chaudhary, Rahul Kumar, Jordan O'Malley, Anna Dubrovska, Xinjiang Wang, Neelu Yadav, David W. Goodrich, Dhyan Chandra
Publikováno v:
Molecular Oncology, Vol 10, Iss 7, Pp 949-965 (2016)
Development of therapeutic resistance is responsible for most prostate cancer (PCa) related mortality. Resistance has been attributed to an acquired or selected cancer stem cell phenotype. Here we report the histone deacetylase inhibitor apicidin (AP
Externí odkaz:
https://doaj.org/article/096b74ce15f345268a0a060d93e2e85a
Publikováno v:
Molecular & Cellular Oncology, Vol 4, Iss 2 (2017)
Prostate cancer variants expressing alternative lineage markers appear at relapse from antiandrogen therapy. We show that loss of the retinoblastoma (RB1) and tumor protein 53 (TP53) genes drives expression of stem cell reprogramming factors, lineage
Externí odkaz:
https://doaj.org/article/7c803a2f071342e5b8cb8ba9a54beeb7
Autor:
Joseph M. Chan, Samir Zaidi, Jillian R. Love, Jimmy L. Zhao, Manu Setty, Kristine M. Wadosky, Anuradha Gopalan, Zi-Ning Choo, Sitara Persad, Jungmin Choi, Justin LaClair, Kayla E. Lawrence, Ojasvi Chaudhary, Tianhao Xu, Ignas Masilionis, Irina Linkov, Shangqian Wang, Cindy Lee, Afsar Barlas, Michael J. Morris, Linas Mazutis, Ronan Chaligne, Yu Chen, David W. Goodrich, Wouter R. Karthaus, Dana Pe’er, Charles L. Sawyers
Publikováno v:
Science
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the molecular mechanisms driving this plasticity remain unclear. Using murine organoid and genetically engineered mouse models, we investigated the causes of lin
Autor:
Andrew S. Kraft, David W. Goodrich, Noel A. Warfel, Stephen M. Black, Virginie Olive, Koichi Okumura, Sathish K.R. Padi, Libia A. Luevano, Neha Singh, Jin H. Song
Cancer resistance to PI3K inhibitor therapy can be in part mediated by increases in the PIM1 kinase. However, the exact mechanism by which PIM kinase promotes tumor cell resistance is unknown. Our study unveils the pivotal control of redox signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae278d3930298bfa95aa897ee9373de6
https://doi.org/10.1158/1535-7163.c.6537757
https://doi.org/10.1158/1535-7163.c.6537757